A randomized clinical study to evaluate the possible antifibrotic effect of zinc sulfate in chronic HCV patient receiving direct-acting anti-viral therapy
Inflammopharmacology · 2025-01 · 33 (1) · 329-339
DOI: 10.1007/s10787-024-01628-3 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Inflammopharmacology, online erschienen am 09.01.2025. Verfasst von Sahar M El-Haggar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, El-Gharbia Government, Tanta, Egypt. Hauptthemen laut MEDLINE: Zinc Sulfate, Hepatitis C, Chronic, Antiviral Agents, Liver Cirrhosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tanta University.
Abstract (Originalsprache)
Objective
This study aimed to assess the potential antifibrotic impact of zinc sulfate in chronic Hepatitis C Virus (HCV) patients receiving direct-acting antiviral therapy.
Methods
This randomized controlled study included 50 chronic HCV-infected patients with fibrosis stage (F1 & F2). Participants were randomly assigned to two groups: Group 1 (Control group, n = 25) received standard direct-acting antiviral therapy for 3 months, while Group 2 (Zinc group, n = 25) received 50 mg/day of zinc sulfate in addition to the standard direct-acting antiviral therapy for the same duration. Baseline and 3-month post-intervention assessments included evaluating serum levels of hyaluronic acid, transforming growth factor beta-1, and fibronectin. Furthermore, indices of liver fibrosis, such as the Fibrosis Index based on the 4 factors (FIB-4) and the Aspartate Transaminase-to-Platelet-Ratio Index (APRI), were calculated during these assessments.
Results
At baseline, the two studied groups had no statistical difference in demographic and laboratory data. After treatment, serum zinc levels significantly increased in the zinc-treated group compared to the control group. Additionally, serum fibronectin and hyaluronic acid levels were significantly reduced in group 2 (zinc group) compared to group 1 (control group). Moreover, zinc group showed lower APRI scores than the control group after a 3-month follow-up period, but there was non-significant difference in FIB-4 scores between the two groups after treatment. Furthermore, total bilirubin levels were reduced after zinc therapy for 3 months.
Conclusions
Administering zinc sulfate could potentially serve as a safe and efficient therapeutic strategy for the management of hepatic fibrosis in individuals with chronic hepatitis C virus. Trial Registration ClinicalTrials.gov identifier: NCT05465434, On 19/7/2022.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, El-Gharbia Government, Tanta, Egypt.
- Faculty of Pharmacy, Menoufia University, Shebin El-kom, Egypt. pg_123922@pharm.tanta.edu.eg.
- Clinical Pharmacy Unit, National Liver Institute, Menoufia University, Shebin El-Kom, Egypt. pg_123922@pharm.tanta.edu.eg.
- Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebin El-Kom, Egypt.
Förderung
- Tanta University
Zitieren
APA
El-Haggar, S. M., Attalla, D. S., Elhelbawy, M., & El-Afify, D. R. (2025). A randomized clinical study to evaluate the possible antifibrotic effect of zinc sulfate in chronic HCV patient receiving direct-acting anti-viral therapy. Inflammopharmacology, 33(1), 329-339. https://doi.org/10.1007/s10787-024-01628-3
Vancouver
El-Haggar SM, Attalla DS, Elhelbawy M, El-Afify DR. A randomized clinical study to evaluate the possible antifibrotic effect of zinc sulfate in chronic HCV patient receiving direct-acting anti-viral therapy. Inflammopharmacology. 2025;33(1):329-339. doi:10.1007/s10787-024-01628-3
BibTeX
@article{ElHaggar2025,
author = {El-Haggar, Sahar M and Attalla, Dina S and Elhelbawy, Mostafa and El-Afify, Dalia R},
title = {A randomized clinical study to evaluate the possible antifibrotic effect of zinc sulfate in chronic HCV patient receiving direct-acting anti-viral therapy},
journal = {Inflammopharmacology},
year = {2025},
volume = {33},
number = {1},
pages = {329--339},
doi = {10.1007/s10787-024-01628-3}
}
EUVIMED